MS4A1 eiwit (inheems, menselijk)

MS4A1

B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7

Native

< 1.0 EU per μg of the protein as determined by the LAL method

1.Immobilized Recombinant Human CD20 (Full Length) Protein-VLP (Cat: 11007-HNAH) at 5 μg/mL (100 μL/well) can bind Obinutuzumab, the EC50 is 1.0-3.0 ng/mL. (Routinely tested) 2.Immobilized Recombinant Human CD20 (Full Length) Protein-VLP (Cat: 11007-HNAH) at 5 μg/mL (100 μL/well) can bind Ofatumumab, the EC50 is 1.4-9.4 ng/ mL. (QC tested) 3.Immobilized Recombinant Human CD20 (Full Length) Protein-VLP (Cat: 11007-HNAH) at 5 μg/mL (100 μL/well) can bind Rituximab, the EC50 is 6-18 ng/mL. (QC tested) 4.Immobilized Recombinant Human CD20 (Full Length) Protein-VLP from competitor A and SINO at 5 μg/mL (100 μL/well) can bind anti-CD20 (Research grade Obinutuzumab biosimilar), the EC50 is 3 ng/mL and 1.7 ng/mL, respectively. The results demonstrated that SINO CD20 (Cat. No. 11007-HNAH) has a higher binding capacity than that of competitor A (Routinely tested) . 5.Immobilized Recombinant Human CD20 (Full Length) Protein-VLP from competitor A and SINO at 5 μg/mL (100 μL/well) can bind anti-CD20 (Research grade Ofatumumab biosimilar), the EC50 is 10.3 ng/mL and 5.4 ng/mL, respectively. The results demonstrated that SINO CD20 (Cat. No. 11007-HNAH) has a higher binding capacity than that of competitor A (Routinely tested) . 5.Immobilized Recombinant Human CD20 (Full Length) Protein-VLP from competitor A and SINO at 5 μg/mL (100 μL/well) can bind anti-CD20 (Research grade Rituximab biosimilar), the EC50 is 19.8 ng/mL and 34.9 ng/mL, respectively. The results demonstrated that SINO CD20 (Cat. No. 11007-HNAH) has a higher binding capacity than that of competitor A (Routinely tested) .

Met1-Pro297

The recombinant human CD20 predicts a molecular mass of 33.08 kDa.

Human